| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Modified Organism
Imojev (Japanese Encephalitis Chimeric Virus Vaccine; JE-CV)
Record information and status
Record ID
114728
Status
Published
Date of creation
2019-05-21 19:30 UTC (austein.mcloughlin@cbd.int)
Date of publication
2019-05-21 19:30 UTC (austein.mcloughlin@cbd.int)

Living Modified Organism identity
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.

LMO name
Imojev (Japanese Encephalitis Chimeric Virus Vaccine; JE-CV)
Transformation event
N/A
Developer(s)
Sanofi-Aventis New Zealand Limited
Level 8, 56 Cawley Street, Ellerslie, Auckland, 1051
Auckland
New Zealand, PO Box 12851
Phone:+ 64 09 5801829
Fax:+ 64 09 5801811
Email:alan.carter@sanofi.com
Url:Sanofi-Aventis New Zealand Limited
Description
Imojev is a modified live, attenuated, viral vaccine designed to provide protection against Japanese encephalitis. The modified virus is chimeric as a result of replacing the pre-membrane and envelope coding sequences from the yellow fever virus strain 17D with the corresponding sequences from the Japanese encephalitis virus strain SA14-14-2.
Recipient Organism or Parental Organisms
The term Recipient organism refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas Parental organisms refers to those that were involved in cross breeding or cell fusion.
Japanese encephalitis virus - JEV SA14-14-2
Yellow fever virus - YFV 17D
Point of collection or acquisition of the recipient organism
Japanese encephalitis virus strain SA 14-14-2 (vaccine strain)
Yellow fever virus strain 17D (vaccine strain)
Characteristics of the transformation process
Vector
Yellow fever virus strain 17D
Techniques used for the modification
  • Gene replacement (Recombinant DNA)
Genetic elements construct
 
5' Noncoding region of Yellow fever virus
0.12 Kb
 
 
Anchored core protein C
0.36 Kb
 
 
pre-membrane protein
0.50 Kb
 
 
Envelope protein
1.50 Kb
 
 
Nonstructural protein 1
1.05 Kb
 
 
Nonstructural protein 2A
0.67 Kb
 
 
Nonstructural protein 2B
0.39 Kb
 
 
Nonstructural protein 3
1.87 Kb
 
 
Nonstructural protein 4A
0.38 Kb
 
 
Peptide 2K
0.07 Kb
 
 
Nonstructural protein 4B
0.75 Kb
 
 
Nonstructural protein 5
2.71 Kb
 
 
3' Noncoding region of Yellow fever virus
0.52 Kb
 
Further details
Notes regarding the genetic elements introduced or modified in this LMO
The chimeric virus was created by replacing the pre-membrane and envelope proteins from Yellow fever virus strain 17D (YFV) with the corresponding sequences from Japanese encephalitis virus (JEV) strain SA14-14-2. Since, the viral genome is single stranded, positive RNA, cDNA was synthesized to replace the genes in the viral genome. After creating the chimeric genome, RNA was synthesized from the cDNA and injected into host cells to create chimeric viral particles.

Translation begins from the 5' noncoding region, synthesizing a single, polyprotein before terminating at the 3' noncoding region. Upon translation, nonstructural protein 3 along with nonstructural protein 2B autocatalyze peptide cleavage. The final viral particles contain YFV anchored protein C (ancC), YFV protein C (processed from ancC), JEV pre-membrane protein (prM), JEV protein M (processed from prM), JEV envelope protein, and viral RNA.

Note:
The chimeric virus was created from live, attenuated YFV and JEV vaccine strains and demonstrated a similar lack of virulence of the parental strains. However, the immune response was sufficient to create immunity to wild-type JEV.
LMO characteristics
Modified traits
  • Modified viral epitopes
Common use(s)
  • Vaccine